Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2013 Results
Date:5/9/2013

llion. The total revenues for the first quarter of 2013 and 2012 each included $1.5 million in Fanapt® royalties received from Novartis.

Total operating expenses for the first quarter of 2013 were $12.3 million, compared to $16.5 million for the first quarter of 2012.  The primary driver of the lower expenses in the first quarter of 2013 was the completion of the tasimelteon Non-24 and Major Depressive Disorder efficacy studies.

Vanda recorded a net loss of $4.2 million for the first quarter of 2013, compared to a net loss of $8.0 million for the same period in 2012.  Diluted net loss per share for the first quarter of 2013 was $0.15, compared to a diluted net loss per share of $0.28 for the first quarter of 2012.

Cash decreased by $9.5 million in the first quarter of 2013, compared to decreases of $10.6 million in the first quarter of 2012 and $14.0 million in the fourth quarter of 2012.  Vanda's Cash as of March 31, 2013 totaled $110.9 million.First Quarter 2013 Key Financial Figures1Three Months EndedMarch 31December 31(in thousands, except per share amounts)  20132012  Change ($)Change (%)Total revenues

$
8,068$
7,920$
482%Research & development  expenses

7,96010,617(2,657)(25%)General & administrative expenses

3,9583,22573323%Non-cash stock-based compensation2

952923293%Net loss

(4,173)(6,369)2,19634%Diluted net loss per share

$
(0.15)$
(0.23)$
.0835% Select Cash Flow Data1 Three Months EndedMarch 31March 31(in thousands)20132012Net cash provided by (used in)  Operating activities

$
(9,125)$
(8,690)  Investing activities

30,47728,861Financing activities

(193)- Select Balance Sheet Data1 March 31December 31March 31(in thousands)201320122012Total cash and marketable securities$
,932$
20,403$

'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
3. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
4. Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
8. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
9. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
10. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
11. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , Apr. 21, 2015 Research and Markets ... addition of the "Complete 2015-16 Induced Pluripotent ... their offering. Stem cell research and ... five decades, as stem cells have the unique ... their unspecialized nature allows them to differentiate into ...
(Date:4/21/2015)... 21, 2015 AbilTo, Inc., the nation,s leading ... submission has been accepted as a presentation to be ... taking place on June 5-6, 2015 in Boston, ... American Diabetes Association, the cost of diabetes to the ... a result of increased inpatient, outpatient, and pharmacy costs, ...
(Date:4/21/2015)... , April 21, 2015  Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... Dr. Mark W. Sawicki , Chief ... Annual BioLogistics Summit in San Francisco, ...
(Date:4/21/2015)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) announced today ... results before market open on Tuesday, April 28, 2015. ... on Tuesday, April 28, 2015, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
Breaking Biology Technology:Global Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3
... AGREEMENT PROVIDES CORGENIX EXCLUSIVE WORLDWIDE RIGHTS TO ... FOR CARDIOVASCULAR INFLAMMATION, DENVER, March 18 ... a worldwide developer and marketer of,diagnostic test ... the Okayama,Prefecture Industrial Promotion Foundation covering new ...
... 18 Visionsense Corp. announces,FDA 510(k) Clearance ... Vision,System. The system is based on a ... targeting Minimal Invasive,laparoscopic and endoscopic Surgery (MIS)., ... enhances MIS surgical,procedures that are under served ...
... 18 /PRNewswire/ - Aegera Therapeutics announced today,the ... trial for AEG33773, a,novel, orally bioavailable small ... diabetic neuropathy. The Phase I study will ... AEG33773 using a randomized,double blind, placebo controlled, ...
Cached Biology Technology:Corgenix Signs Technology Licensing Agreement With Japanese Government 2Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... virus (HCV) are at an increased risk of developing ... a study published in the May 8, 2007, issue ... Researchers from the National Cancer Institute (NCI), part of ... Medicine, found that HCV infection increased the risk of ...
... certain neurodegenerative diseases, such as mad cow disease or ... of infectious protein called a prion. Remarkably, in recent ... beneficial roles in biology, and prions even may act ... , But although prions have received a great deal ...
... central Catalonia, is so delicate that experts cannot get physically ... the years since the tracks were discovered they have been ... weathered and eroding at a rapid rate. , To ... near-vertical rock faces. , Palaeontologists feared the tracks could ...
Cached Biology News:Risk of lymphoma increases with hepatitis C virus infection 2Scientists identify prion's infectious secret 2Scientists identify prion's infectious secret 3Diminishing dinosaur steps saved by laser and laptop 2Diminishing dinosaur steps saved by laser and laptop 3
Human SOST Affinity Purified Polyclonal Ab...
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Human FADD Affinity Purified Polyclonal Ab...
... triple quadrupole 1200L sets the new ... environment - incorporating the latest technologies ... liquid chromatography analytical needs. The ... the Transmission Quadrupole Analyzer provide superior ...
Biology Products: